Add time:08/31/2019         Source:sciencedirect.com

BackgroundOral inhalation is the main drug delivery route for treating obstructive lung conditions. Thus, many inhaler devices with various design and pharmaceutical formulation have been introduced. The fine particle dose (FPD) and mass median aerodynamic diameter (MMAD ≤ 5 μm) of the aerosol delivered dose (DD) dictate the therapeutically effective peripheral lung deposition. This study evaluated the in vitro aerosol emission performance of Tiotropium bromide (cas 136310-93-5) emitted from Spiriva® Respimat® soft mist inhalers (R) after living under patients’ real-world, post-dispensing handling environments.

We also recommend Trading Suppliers and Manufacturers of Tiotropium bromide (cas 136310-93-5). Pls Click Website Link as below: cas 136310-93-5 suppliers